Securities code: 600807 securities abbreviation: Jinan High-Tech Development Co.Ltd(600807) Announcement No.: pro 2022-005 Jinan Chengdu Hi-Tech Development Co.Ltd(000628) Co., Ltd
Stock trading risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important contents and risk tips:
1. When the company acquires part of the equity of Shandong aikewei Biotechnology Co., Ltd. (hereinafter referred to as “aikewei biotechnology”), there are the following risks:
(1) The operating revenue and net profit of aikewei biology decreased year-on-year, its nucleic acid detection operating revenue and market share accounted for a small proportion, and its gross profit margin was lower than that of the same industry.
From January to September 2021, aikewei biological realized an operating revenue of 124.6153 million yuan, a year-on-year decrease of 11.33%; The net profit was 11.8329 million yuan, a year-on-year decrease of 49.57%. Among them, from January to September 2021, the revenue of actway biological nucleic acid testing reagents and nucleic acid testing services was 20.3 million yuan, a year-on-year decrease of 52.57%, and the revenue of such products accounted for only 2.60% of the operating revenue of the listed company in the same period, accounting for a small proportion, and its market share was relatively small; The gross profit margin of aikewei biological nucleic acid detection reagent and nucleic acid detection service products is about 15%, which is lower than the average level of major listed companies in the same industry.
(2) The approval of amplification reagent related to nucleic acid detection is uncertain, and the nucleic acid detection reagent developed by aikewei biology has not been applied in clinic.
Nucleic acid detection is divided into three stages: sampling, extraction and amplification. At present, aikewei biology has only sampling, extraction and other reagent products or equipment to obtain the medical device production Filing Certificate issued by the local market supervision and Administration Bureau; However, the amplification reagent needs to be approved by the evaluation center of the State Drug Administration, which has strong uncertainty. At present, aikewei’s biological customers are all in China, mainly for government laboratory customers, and the nucleic acid detection reagent developed by aikewei has not been applied to clinic.
(3) At present, the equity transfer registration has not been completed, which will not be included in the consolidation scope of the company’s 2021 financial statements and will not have an impact on the company’s 2021 financial statement performance.
(4) The company has no relevant personnel and technical reserves in the biomedical field, so there is a risk of business integration. The business scope of aikewei biology is quite different from the company’s main business. The company has no relevant personnel, technology and capital reserves in the biomedical field. It is uncertain whether the company can effectively integrate and manage aikewei biology after this merger.
(5) The risk that the operation fails to meet expectations and the performance commitments cannot be realized. If the future operation of aikewei biology fails to meet expectations, the performance commitment cannot be realized, which will affect the overall operating performance and profitability of the company.
2. The company plans to sell 100% equity of nqm gold 2 Pty Ltd (hereinafter referred to as “nqm company”), which has the following risks: (1) there is a risk of uncertainty about whether the transaction can be implemented: the transaction needs to be approved by the competent authorities and regulatory authorities, and there is uncertainty about whether it can be implemented.
(2) Risk of short-term decline in the company’s performance: after the company sells the equity of nqm, there is a risk of affecting the company’s operating performance in the short term.
3. The company’s net profit attributable to the parent company in recent one year and one period both suffered losses and fell sharply year-on-year. In 2020, the net profit attributable to the shareholders of the listed company was -824.9899 million yuan, a year-on-year decrease of 1406.93%. From January to September 2021, the net profit attributable to the shareholders of the listed company was -165.1923 million yuan, a year-on-year decrease of 110.1196 million yuan. The company’s performance was at a loss in recent years.
4. The short-term increase of the company’s stock deviates seriously from the Shanghai stock index and the same industry index, and there is a secondary market trading risk. On January 14, 2022, the company’s stock rose again, and the company’s stock trading fluctuated significantly. The cumulative increase deviated from the Shanghai stock index by 37.54% and the same industry index by 40.46%. The short-term increase of the company’s stock was significantly higher than that of the Shanghai stock index and the same industry index in the same period.
Recently, the company’s stock trading has fluctuated greatly. The cumulative deviation of the closing price increase from the value for three consecutive trading days on January 11, January 12 and January 13, 2022 is more than 20%, which constitutes an abnormal fluctuation of stock trading. On January 14, 2022, the company’s stock rose again, with the cumulative increase deviating from the Shanghai stock index by 37.54% and the same industry index by 40.46%, The short-term increase of the company’s shares was significantly higher than that of the Shanghai index and the same industry index in the same period. The company now explains relevant matters and risks. At the same time, the company specially reminds investors to pay attention to investment risks, avoid speculation on concept themes, make rational decisions and invest prudently.
1、 The company’s subsidiary acquires part of the equity of aikewei biology, which has the following matters and risks:
1. The operating revenue and net profit of aikewei biology decreased year-on-year, its nucleic acid detection operating revenue and market share accounted for a small proportion, and its gross profit margin was lower than that of the same industry.
From January to September 2021, aikewei biological realized an operating revenue of 124.6153 million yuan, a year-on-year decrease of 11.33%; The net profit was 11.8329 million yuan, a year-on-year decrease of 49.57%. Among them, from January to September 2021, the revenue of actway biological nucleic acid testing reagents and nucleic acid testing services was 20.3 million yuan, a year-on-year decrease of 52.57%, and the revenue of such products accounted for only 2.60% of the operating revenue of the listed company in the same period, accounting for a small proportion, and its market share was relatively small; The gross profit margin of aikewei biological nucleic acid detection reagent and nucleic acid detection service products is about 15%, which is lower than the average level of major listed companies in the same industry.
2. The approval of amplification reagent related to nucleic acid detection is uncertain, and the nucleic acid detection reagent developed by aikewei biology has not been applied in clinic.
Nucleic acid detection is divided into three stages: sampling, extraction and amplification. At present, aikewei biology has only sampling, extraction and other reagent products or equipment to obtain the medical device production Filing Certificate issued by the local market supervision and Administration Bureau; However, the amplification reagent needs to be approved by the evaluation center of the State Drug Administration, which has strong uncertainty. At present, aikewei’s biological customers are all in China, mainly for government laboratory customers, and the nucleic acid detection reagent developed by aikewei has not been applied to clinic.
3. The equity transfer registration procedures of aikewei biology have not been completed and will not be included in the company’s 2021 financial statements.
At present, the equity transfer registration procedures of aikewei biology have not been completed, which will not be included in the consolidation scope of the company’s 2021 financial statements and will not have an impact on the company’s 2021 financial statement performance.
4. The company has no relevant personnel and technical reserves in the biomedical field, so there is a risk of business integration. The business scope of aikewei biology is quite different from the company’s main business. The company has no relevant personnel, technology and capital reserves in the biomedical field. It is uncertain whether the company can effectively integrate and manage aikewei biology after this merger.
5. The risk that the operation fails to meet expectations and the performance commitments cannot be realized.
The net profit of aikewei biology in the first half of 2021 was 5.0242 million yuan, Xilong Scientific Co.Ltd(002584) promised that aikewei biology would realize the audited after tax net profit of no less than 190 million yuan from 2022 to 2024. If the future operation of aikewei biology did not meet expectations, the performance commitment could not be realized, which would affect the overall operating performance and profitability of the company.
2、 The company plans to sell 100% equity of nqm company, which has the following risks:
1. There is uncertainty risk whether it can be implemented.
The company’s sale of 100% equity of nqm company needs to be approved by the competent authorities and regulatory authorities, and there is uncertainty whether it can be implemented;
2. Risk of short-term decline in the company’s performance.
As of the first half of 2021, mining revenue accounted for about 59.2% of the company’s operating revenue. After the company sold nqm’s equity, there was a risk of affecting the company’s operating performance in the short term.
3、 The company’s net profit and net profit attributable to the parent company have suffered losses in recent years, and the risk of significant year-on-year decline.
In 2020, the net profit attributable to the shareholders of the listed company was -824.9899 million yuan, a year-on-year decrease of 1406.93%. From January to September 2021, the net profit attributable to the shareholders of the listed company was -165.1923 million yuan, a year-on-year decrease of 110.1196 million yuan, and the company’s performance was at a loss in recent years.
4、 The short-term increase of the company’s stock deviates seriously from the Shanghai stock index and the same industry index, and there is a secondary market trading risk.
The closing price of the company’s stock has increased by 35.52% in the last four trading days, 37.54% away from the Shanghai stock index and 40.46% away from the same industry index. The short-term increase of the stock is higher than that of the Shanghai stock index and the same industry index in the same period. There is a secondary market transaction risk. Please pay attention to the secondary market transaction risk, make rational decisions and invest prudently.
The information disclosure media designated by the company are Shanghai Securities News, China Securities News and the website of Shanghai Stock Exchange. The information about the company shall be subject to the information published in the above designated media.
It is hereby announced.
Jinan Chengdu Hi-Tech Development Co.Ltd(000628) Co., Ltd
Board of directors
January 15, 2022
